DSIP dosing research protocols — the figures studies used, reconstitution, handling

“What is the DSIP dose?” is one of the most-searched questions about Delta Sleep Inducing Peptide — and the honest answer starts by refusing the premise twice over. First, there is no validated human dose of DSIP for any purpose, because DSIP is not an approved medicine in any major jurisdiction and has never been through a dose-finding programme that would establish one. Second, the founding pharmacology that the circulating figures echo was never expressed in flat milligrams at all — it was dosed in nmol/kg, molar amount per kilogram of body weight. That single fact is why the DSIP dosing literature looks so unlike the round-milligram numbers people expect, and it is the thread this spoke pulls on. Every figure below is described as what a study administered, not as a protocol to follow.

Why there is no validated human dose

The first thing to settle, before any number appears, is what kind of object a “DSIP dose” actually is. It is not an approved dosing instruction, because DSIP is not an approved medicine anywhere in the major regulatory world — there is no regulator-reviewed label, no marketed strength, and no dose-ranging programme that ever ran to registration. The figures that circulate on forums and vendor pages are extrapolations: they reproduce amounts that appeared in a handful of older research reports and present them as though they were established protocols. They are not.

There is a second, deeper reason the dose question has no clean answer, and it is specific to DSIP. As the parent synopsis sets out, decades of work have failed to identify a definitive high-affinity DSIP receptor. Without a characterised receptor there is no rational dose-response basis — no binding curve, no occupancy model, none of the pharmacology that lets a field reason from “this much molecule” to “this much effect”. The consolidated 1986 review by Graf and Kastin laid out exactly this receptor-and-mechanism problem, and the picture has not fundamentally changed since [3]. A field that has not settled the mechanism has certainly not settled a human dose. Read every figure that follows as “what these papers administered”, never as “what to take”.

There is no validated human dose of DSIP — and because no high-affinity receptor has been identified, there is no dose-response framework to build one on. The circulating numbers describe old experiments, not a protocol for any person to follow.

The nmol/kg nuance — molar dosing, not flat milligrams

Here is the detail that almost every popular DSIP page skips, and the reason the historical numbers look so strange. The founding DSIP pharmacology was not dosed in flat milligrams — it was dosed in nmol/kg, nanomoles of peptide per kilogram of body weight. That is a molar quantity scaled to the animal or volunteer, which is how rigorous peptide pharmacology of that era expressed dose, and it is the unit the primary papers actually report.

• The 1981 human sleep study. Schneider-Helmert and colleagues administered DSIP at 25 nmol/kg intravenously to six volunteers and reported on sleep parameters [1]. This is the most concrete human-administration figure in the public record — a single small study describing what it gave its participants, expressed in molar-per-body-weight terms, not a regimen on offer here.
• The rabbit blood-brain-barrier work. Monnier and colleagues used roughly 30 nmol/kg intravenously in rabbits in the work demonstrating that DSIP crosses the blood-brain barrier [2]. Again the unit is nmol/kg — an animal figure, in an animal route, gathered to study transport rather than to set a dose.
• The order of magnitude. Across this lineage the administered amounts cluster in the low tens of nmol/kg. They are small, molar quantities — not the round milligram figures that vendor pages tend to invent by working backwards from a vial size.

Because these figures are molar, comparing them to a milligram label requires a conversion, and the conversion is the whole point. DSIP’s molecular weight is approximately 849 Da — that is, about 849 micrograms per micromole, or 0.849 µg per nmol. So 25 nmol/kg multiplies out to about 21 µg/kg(25 × 0.849 ≈ 21.2), and 30 nmol/kg to about 25 µg/kg. These are research-reference computations that let you read the historical molar figures against a milligram-labelled vial. They are arithmetic, not advice — nothing here is a recommendation that any person take any amount of DSIP.

25 nmol/kg is not a number you can compare to a milligram label until you multiply by the molecular weight. At ~849 Da that works out to about 21 µg/kg — a unit-conversion, not a dose to follow.

Route note — what the founding studies used

The route matters as much as the amount, and it is another place where the historical record and the modern market diverge. The founding DSIP figures came from intravenous administration in the human study [1] and from intravenous — and, in some animal work, intraventricular — delivery in the preclinical literature [2]. Those are research routes, chosen to study the molecule under controlled conditions, not a use instruction and not a route this article endorses for anything.

The consequence is that the human pharmacokinetics of DSIP by other routes are essentially uncharacterised. There is no rigorous published profile of absorption, distribution, or clearance for the delivery methods that circulate informally, which means the nmol/kg figures from the intravenous studies cannot be assumed to translate to any other route. Graf and Kastin’s review discusses the pharmacokinetic picture and its limits [3]; the short version is that the route the founding numbers came from is not the route most informal accounts assume, and the gap between the two has never been formally bridged.

Reconstitution & the concentration math

DSIP is, chemically, one of the more forgiving research peptides to handle. It is a small nonapeptide — Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight approximately 849 Da, supplied as the acetate salt — that is water-soluble and carries nodisulphide bridges, so it dissolves readily and is not prone to the oxidative-folding problems that complicate larger, cysteine-containing peptides. That same 849 Da figure is what underlies both the molar-to-mass conversion above and the parent-ion check on a certificate of analysis.

Reconstitution mechanics, as a laboratory-handling procedure, are simple: introduce bacteriostatic water — sterile water with about 0.9% benzyl alcohol as a preservative — slowly down the inside wall of the vial rather than aiming the stream at the powder cake, then swirl gently to dissolve. Never shake: shaking shears and can denature the peptide. The general diluent and documentation framework lives in our how to reconstitute research peptidesguide. The math below shows how a chosen mass in milligrams maps onto syringe units — it is laboratory handling arithmetic, not a use instruction.

Storage & handling

Storage discipline is straightforward but worth getting right. As a lyophilised powder DSIP is stable at -20°C, protected from light, for years; once reconstituted in bacteriostatic water it is generally kept refrigerated at 2-8°Cand remains usable for several weeks within the window stated on the vendor’s documentation. Bacteriostatic water’s benzyl alcohol preservative is what allows a reconstituted multi-use vial to remain usable across that window rather than being a single-use preparation.

The handling subtlety specific to this molecule is a quality-control one. Precisely because DSIP is a short, water-soluble peptide that is comparatively easy to synthesise, the barrier to manufacture is low — which means purity varies widely across vendors, and verification matters more, not less. A research-grade material should arrive with a third-party RP-HPLC purity assay of ≥98% peak area at λ=214 nm, batch-numbered, plus mass-spectrometry confirmation of the parent ion at roughly 849 Da [M+H]⁺, consistent with the nonapeptide identity. Without that documentation, the “dose” implied by the label is only as trustworthy as the mass actually in the vial — and the nmol/kg-to-mass conversion above only holds if the mass on the label is real.

Cycles and “protocols” — convention vs evidence

The multi-week-course conventions that circulate — a run of consecutive days, a break, a repeat — are presented online as though they were established protocols. They are not derived from any published human dose-response work. They are convention: patterns that propagate through forums and vendor pages, often inventing a milligram regimen out of thin air without reference to the molar figures the actual studies used.

The honest distinction is between what the literature describes and what it validates. The published record describes DSIP administered intravenously at 25 nmol/kg in a single small human sleep study [1] and at around 30 nmol/kg in rabbit transport work [2]. None of that amounts to a controlled programme that validates any particular cycle length, dose, or frequency for general use, and the literature review is clear that the underlying mechanism remains unsettled [3]. So a “DSIP protocol” is a convention to recognise when reading the literature — not a dose-response-derived schedule, and not a recommendation made here. Nothing in this article describes DSIP treating insomnia or any other condition.

A circulating “DSIP protocol” is convention, not evidence. No controlled human programme has validated a particular dose, frequency, or course length — the published figures describe a handful of old experiments in molar units, not a protocol for people.

Related reading in the DSIP cluster

For what DSIP is and where its research record stands — including the receptor gap that underlies the whole dose question — start with the DSIP parent synopsis. For the molecular biology, see DSIP mechanism research; for the EEG and slow-wave-sleep literature, see DSIP sleep research. For general diluent and documentation handling, see how to reconstitute research peptides, and run any vial-size / concentration / draw-volume combination through the free reconstitution calculator. Supply: DSIP 5 mg research-consultation page.

Further reading

Peer-reviewed citations used inline:

• [1] Schneider-Helmert et al. — Int J Clin Pharmacol Ther Toxicol 1981. Human sleep study; DSIP administered at 25 nmol/kg intravenously in six volunteers — the most concrete human-administration figure in the public record, reported in molar-per-body-weight terms. PMID 6895513.
• [2] Monnier et al. — Experientia 1977. DSIP crosses the blood-brain barrier in the rabbit; administered at roughly 30 nmol/kg intravenously — an animal figure in an animal route. PMID 590449.
• [3] Graf & Kastin — Peptides 1986. DSIP chemistry and biology — consolidated review covering the receptor-search problem, dose, and pharmacokinetic context. PMID 3550726.

Last reviewed 12 June 2026. DSIP is not an approved medicine in any major jurisdiction; this article is research education and not medical advice, and nothing here describes a dose for any person to take or claims DSIP treats any condition. Wellness Labs supplies DSIP as research-grade lyophilised powder for non-clinical investigation — research use only, not for human consumption. Editorial inbox: info@uaewellnesslab.com.